In a new paper entitled “FMN2 is a novel regulator of the cyclindependent kinase inhibitor p21”, published in the journal Cell Cycle, the Lamond and Rocha groups further analysed the role of FMN2in the important tumour suppressor pathway mediated by p14ARFand p53. This study extends the findings published earlier this year in Molecular Cell. Using a combination of imaging, proteomic and biochemical analysis, our new data indicates that the N-terminal part of the FMN2 protein, is the most important functional region of the molecule for the control of the p21 cell cycle inhibitor. Our combined studies reveal that FMN2 is a potential biomarker for proliferative disorders and could be a future target for therapy.